Korea Bio-Gen Co.Ltd (318000) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Korea Bio-Gen Co.Ltd stock KRW 4,998, price KRW 2,195, upside +127.7%, quality 62 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 2,195 KRW – 18,575 KRW · fair‑value band 3,691 KRW – 6,305 KRW · the 2,195 KRW price screens below the 4,998 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Korea Bio-Gen Co.Ltd in your weekly email
Every Wednesday you see whether Korea Bio-Gen Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally.
Show moreShow less
The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as silicon inorganic chemical materials, organic materials, bio-materials, and others.
It serves electric and electronics, automobile, construction, chemical related industries of food and pharmaceuticals, petrochemicals, etc. The company was formerly known as Korea Bio-Gen Co.,Ltd. KBG Corp. was founded in 2001 and is headquartered in Cheonan-si, South Korea.
Stock analysis
Korea Bio-Gen Co.Ltd (318000) currently trades at 2,195 KRW, while our model-based Fair Value estimate is 4,998 KRW, implying the stock looks roughly 56% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 9,083 KRW per share, and 22 of the 24 models we run sit above the 2,195 KRW price.
Bear case: the Dividend Discount group reads lowest at 887.65 KRW, and 2 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 3,691 KRW (bear) to 6,305 KRW (bull), the price of 2,195 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Basic Materials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Korea Bio-Gen Co.Ltd reported revenue of 23.9B KRW in FY2025 versus 27.2B KRW in FY2021, a compound −3.2%/yr. Reported net income was 2.6B KRW in FY2025, compounding −10.3%/yr from FY2021.
Key figures
Market cap 19.1B KRW (≈ $14.1M) Micro · P/E ratio 12.0 · P/S ratio 0.84 · EPS (TTM) 183.26 KRW · Dividend yield 2.7% · Net margin 6.9% · Return on equity 3.4% · Return on assets (EBIT) 9.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).
What moves the price
The share trades about 56% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at 128%, 318000 screens cheaper than that median.
Fair Value models
Bear3,691 KRWFair Value 4,998 KRWBull6,305 KRW
Price 2,195 KRW · Upside +127.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (105.70 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.60/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.5%
Dividend (yield on the price)2.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 13%
⚠ Revenue per share shrinking 13.5%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 728 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Top 25%
Fair Value upside+122.1% · Top 25%
Profitability
Return on equity (12 months)3.4% · Below median
Return on assets5.0% · Above median
Net margin (12 months)6.9% · Above median
Operating margin (12 months)−4.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)1.1% · Below median
Dividend yield (12 months)2.7% · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Korea Bio-Gen Co.Ltd (318000) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 4,998 KRW versus a price of 2,195 KRW, about +128% upside (undervalued).
What is the fair value of 318000?
Our model-based fair value for Korea Bio-Gen Co.Ltd is 4,998 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 2,195 KRW.
What is the quality score of 318000?
Korea Bio-Gen Co.Ltd has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Korea Bio-Gen Co.Ltd (318000)?
Our model-based price target is the fair value of 4,998 KRW (as of Nov 3, 2026) from 24 valuation models. Cautious scenario 3,691 KRW, optimistic scenario 6,305 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Korea Bio-Gen Co.Ltd stock forecast for 2026?
Our models put fair value at 4,998 KRW, about +128% upside versus a price of 2,195 KRW (undervalued). Cautious scenario 3,691 KRW, optimistic scenario 6,305 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Korea Bio-Gen Co.Ltd (318000)?
Korea Bio-Gen Co.Ltd reported trailing-twelve-month revenue of about 23.3B KRW (latest available figure, as of Nov 3, 2026).
Does Korea Bio-Gen Co.Ltd pay a dividend?
Korea Bio-Gen Co.Ltd currently shows a dividend yield of 2.73% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Korea Bio-Gen Co.Ltd (318000) and when is the ex-dividend date?
Korea Bio-Gen Co.Ltd pays a dividend of 60.00 KRW per share a year, a dividend yield of 2.7%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2019. The payout ratio is 32.7% of earnings. Free cash flow covers the dividend 13.18 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Korea Bio-Gen Co.Ltd (318000)?
For today's price to be fair in a discounted-cash-flow model, Korea Bio-Gen Co.Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.9 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 318000 use?
Our models discount Korea Bio-Gen Co.Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.39, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Korea Bio-Gen Co.Ltd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Korea Bio-Gen Co.Ltd (318000) delivered so far?
Over the past 5 years revenue at Korea Bio-Gen Co.Ltd grew +3.9 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Korea Bio-Gen Co.Ltd (318000) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into Korea Bio-Gen Co.Ltd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Korea Bio-Gen Co.Ltd (318000)?
The free-cash-flow yield on the price is 36.01 %: that much free cash flow Korea Bio-Gen Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Korea Bio-Gen Co.Ltd (318000)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Korea Bio-Gen Co.Ltd it is 4,998 KRW per share (as of Nov 3, 2026), against a price of 2,195 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Korea Bio-Gen Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 318000 trades below its calculated fair value: price 2,195 KRW, fair value 4,998 KRW, a gap of about +128% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 318000?
No. The price is what the market pays today (2,195 KRW); the fair value is what the company's own numbers justify (4,998 KRW). For Korea Bio-Gen Co.Ltd the two are 2,803 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Korea Bio-Gen Co.Ltd worth?
The market values Korea Bio-Gen Co.Ltd at about 19.1B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 2,195 KRW; our models calculate a fair value of 4,998 KRW per share.
What do the bullish and bearish scenarios say about 318000?
Our models span a range for Korea Bio-Gen Co.Ltd: cautious scenario 3,691 KRW, base 4,998 KRW, optimistic 6,305 KRW per share (as of Nov 3, 2026, price 2,195 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 318000?
Korea Bio-Gen Co.Ltd trades at a price-to-earnings ratio of 12.0 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4,998 KRW is built from several models across several years. Other multiples: P/B 0.4, P/S 0.8, EV/EBITDA 5.0.
How solid is the balance sheet of Korea Bio-Gen Co.Ltd (318000)?
Balance-sheet figures for Korea Bio-Gen Co.Ltd (as of Nov 3, 2026): return on equity 3.4%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 318000 from its 52-week high?
Korea Bio-Gen Co.Ltd trades at 2,195 KRW, about 56% below its 52-week high of 5,023 KRW and at the low of 2,195 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 4,998 KRW is for.
Which stocks are comparable to Korea Bio-Gen Co.Ltd?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Korea Bio-Gen Co.Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 2,195 KRW, calculated fair value 4,998 KRW (+128%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 318000 calculated?
We run Korea Bio-Gen Co.Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 4,998 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Korea Bio-Gen Co.Ltd currently trades 56% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Korea Bio-Gen Co.Ltd (318000)?
The closing price on Nov 9, 2026 was 2,195 KRW. Our model-based fair value is 4,998 KRW, about +128% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Korea Bio-Gen Co.Ltd right now?
The price is below even our cautious bear case (3,691 KRW). The market is more pessimistic than our downside scenario. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Korea Bio-Gen Co.Ltd
How large is the market capitalisation of Korea Bio-Gen Co.Ltd (318000)?
The market capitalisation of Korea Bio-Gen Co.Ltd is 19.1B KRW (≈ $14.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Korea Bio-Gen Co.Ltd (318000)?
The price-to-sales ratio of Korea Bio-Gen Co.Ltd is 0.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Korea Bio-Gen Co.Ltd (318000)?
Earnings per share at Korea Bio-Gen Co.Ltd are 183.26 KRW (price ÷ EPS = P/E 12.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Korea Bio-Gen Co.Ltd (318000)?
The dividend yield of Korea Bio-Gen Co.Ltd is 2.7% (payout 32.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Korea Bio-Gen Co.Ltd (318000)?
The net margin of Korea Bio-Gen Co.Ltd is 6.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Korea Bio-Gen Co.Ltd (318000)?
The return on equity (ROE) of Korea Bio-Gen Co.Ltd is 3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Korea Bio-Gen Co.Ltd (318000)?
On an EBIT basis the return on assets of Korea Bio-Gen Co.Ltd is 9.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Korea Bio-Gen Co.Ltd (318000)?
The operating margin of Korea Bio-Gen Co.Ltd is −4.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Korea Bio-Gen Co.Ltd (318000)?
Revenue at Korea Bio-Gen Co.Ltd is growing +1.1% versus a year earlier (3y avg −0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Korea Bio-Gen Co.Ltd (318000)?
Earnings per share at Korea Bio-Gen Co.Ltd are growing +53.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Korea Bio-Gen Co.Ltd (318000) carry?
The net debt of Korea Bio-Gen Co.Ltd is 2.0B KRW (fiscal year 2022, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Korea Bio-Gen Co.Ltd in the live analysis
One click puts Korea Bio-Gen Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 3, 2026